Wang H, et al. – The scientists applied mass spectrometry–based targeted proteomics for the quantification of mutant speckle–type POZ protein (SPOP) in prostate cancer. They described that PRISM (high–pressure, high–resolution separations coupled with intelligent selection and multiplexing)–SRM (selected reaction monitoring) enables multiplexed, isoform–specific detection of mutant SPOP proteins in cell lysates and provided significant potential in biomarker development for prostate cancer.